David Steinberg


Jefferies Analyst Sees Long-Term Growth Potential for Horizon Pharma PLC (HZNP) Despite Actimmune FA Phase 3 Flop

Horizon Pharma PLC (NASDAQ:HZNP) has had a recent misstep on its hands with a Phase 3 flop in its Actimmune Friedrich’s Ataxia (FA) …

Analysts Disagree Over Significance of Akorn, Inc.’s Financial Errors (AKRX)

Akorn, Inc. (NASDAQ:AKRX) announced on Friday that it will have to restate financials from 2014 due to accounting errors.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts